医疗科技风险投资悖论

EMERGING TECH RESEARCHThe Medtech VC Paradox PitchBook Data, Inc. Nizar TarhuniExecutive Vice President ofResearch and Market Intelligence Paul CondraGlobal Head of PrivateMarkets Research Fewer deals, slower exits, yet growth capital is surging James UlanDirector of EmergingTechnology Research PitchBook is a Morningstar company providing the most comprehensive, mostaccurate, and hard-to-find data for professionals doing business in the private markets. Institutional Research Group Analysis Aaron DeGagne, CFASenior Research Analyst,Healthcareaaron.degagne@pitchbook.com Key takeaways •Medtech capital skews to growth:Deal value has rebounded toward 2020-2021highs, but most activity is concentrated in later-stage financings, where $100million-plus rounds are increasingly common. Seed and Series A funding remainsthin, leaving early-stage innovators with fewer options. Data Sara GoodData Analyst pbinstitutionalresearch@pitchbook.com •The long road to liquidity:Medtech companies face paths longer than 10 yearsfrom founding to exit, reflecting the challenge of clinical validation, regulatoryclearance, payer coverage, and adoption. Patient capital and well-constructedmilestones are essential for companies to realize strong outcomes. PublishingDesigned byDrew Sanders Published on October 15, 2025 •Acquirers want proof, not promise:Strategics overwhelmingly favor FDA-cleared, reimbursement-backed, and adoption-ready businesses. Strong clinicalevidence and market traction are prerequisites for M&A. Contents •The overlooked early stage:Competition at the growth stage is strong, thoughinvestors are retreating from riskier bets. Those willing to back disciplined seedand Series A opportunities may capture attractive entry points into the nextwave of medtech innovators. •AI dominates VC flows:Nearly 70% of total VC deal value in North America—and a comparable share for top medtech startups—now goes to AI-enabledstartups. This concentration carries risk: If reimbursement tailwinds fade fornovel AI technology, or if regulatory scrutiny ramps up, today’s momentum couldbe fragile. •Valuation divergence accelerating:Growth-stage rounds often reach $100million-plus at steep valuations, while early-stage pricing has stabilized. Lowervaluations for public firms—highlighted in ourMedtech Comp Sheet andValuation Guide—are weighing on VC investment downstream. The medtech VC paradox Medtech venture funding appears to be rebounding as quarterly deal value hasclimbed toward levels not seen since the 2020-2021 boom, and 2025 is set tooutpace the muted activity in recent years. Still, this recovery is uneven, with mostof the momentum concentrated in later-stage financings, while the early-stageengine continues to show signs of strain. In this report, we examine current VC funding dynamics in medtech—where capitalis flowing, how activity varies across stages, and key implications for startups andinvestors in the sector. We also assess what this uneven recovery suggests for thesector’s exit outlook and its innovation pipeline in the years ahead. Early-stage deal flow has plummeted since its 2021 peak, with far fewer seed and SeriesA companies attracting VC backing than just a few years ago. In contrast, venture-growth rounds have expanded, accounting for an outsized share of total deal value. Theresult: Medtech venture funding is increasingly tilted toward established players withexisting regulatory traction, payer engagement, and scaled solutions, while youngerstartups are struggling to secure the capital needed to reach escape velocity. Even as the IPO window has remained mostly closed, barring a few exceptions,capital has continued to consolidate upmarket, with large venture fundsconcentrating bets on companies that already look acquisition- or IPO-ready. AI hasalso clearly played a key role in driving funding and attracting dollars to companiesthat can frame themselves as data-driven platforms rather than single-productdevice makers. In North America, about 70% of total VC deal value is going to AI& machine learning (ML) startups, including companies developing foundationalmodels and tools and those embedding AI into their operations.1Additionally,data through Q2 2025 showed that close to three-fifths of total capital in the topmedtech VC deals was concentrated in AI-enabled companies. This contrasts withtraditional market fundamentals in medtech, with slow reimbursement decisions, In North America, about 70% of total VCdeal value is going to AI & machine learning(ML) startups. costly clinical validation, and commercialization requiring significant salesinvestment. Investors at the growth stage can justify bridging companies throughthese hurdles, but seed and early-stage backers face the prospect of underwriting amuch longer lifecycle. This leads us to a paradox in medtech VC investment: On the surface, capitaldeployment looks strong, yet a thinner pipeline at the seed and early stages meansfewer companies